Available 24/7 for Urgent On-Site or Virtual Consulting
As the pharmaceutical industry moves toward advanced aseptic technologies, navigating a sterile manufacturing FDA inspection in 2026 requires a specialized focus on contamination control and automated integrity. This guide explores the latest audit trends—from the impact of Revised Annex 1 to the rise of robotic filling lines—ensuring your facility maintains the highest level of sterility assurance and audit readiness.
Navigating a medical device contract manufacturer FDA inspection requires a rigorous alignment between sponsor expectations and facility operations. As we move into 2026, the risks associated with outsourced manufacturing—ranging from purchasing controls to technical documentation gaps—have intensified. This guide identifies the top inspectional risks and provides a blueprint for maintaining a state of perpetual audit readiness.
In the high-stakes world of pharmaceutical and medical device manufacturing, data is the most valuable asset. This 2026 guide breaks down the core components of an FDA data integrity inspection, identifying the specific questions investigators prioritize during audits. From ALCOA+ principles to electronic audit trails, discover how to protect your facility from 483 observations and warning letters.
As the frontier of regenerative medicine expands, navigating cell and gene therapy FDA inspections has become a critical milestone for biotech innovators. This 2026 guide explores what investigators prioritize—from aseptic processing and viral clearance to complex chain-of-identity protocols. Learn how to align your quality systems with CBER expectations and ensure your advanced therapy reaches the market securely.
Navigating a regulatory audit requires a precise understanding of the legal boundaries governing federal oversight. This comprehensive 2026 guide explores the extent of FDA inspection authority, identifying exactly what investigators can legally request, which records are shielded from review, and how manufacturers can protect their interests while remaining fully compliant during on-site assessments.
As regulatory scrutiny intensifies, navigating a dietary supplement FDA inspection requires a deep dive into 21 CFR 111 compliance. This 2026 guide highlights the most frequent GMP violations—from identity testing failures to inadequate batch records—and provides actionable strategies for manufacturers and distributors to remain audit-ready in an increasingly data-driven environment.
The medical device industry is facing a pivotal shift as the FDA transitions from the legacy Quality System Regulation (21 CFR 820) to the new Quality Management System Regulation (QMSR). This comprehensive guide explains the core differences, the alignment with ISO 13485:2016, and what manufacturers must prioritize to ensure a successful FDA QMSR inspection outcome in 2026.
Ensuring regulatory compliance requires more than just hiring a third-party manufacturer. This guide explores the critical gaps in CDMO FDA inspection readiness, highlighting the common mistakes sponsors make during the oversight process. Learn how to strengthen your quality agreements, improve data integrity, and ensure your external partners remain audit-ready in the evolving 2026 landscape.
As the regulatory landscape shifts, the introduction of the FDA one day inspections biologics protocol has sent ripples through the pharmaceutical industry. This 2026 guide examines the strategic shift toward rapid assessments, the technological requirements for biologics manufacturers, and how firms must adapt their quality management systems to survive a compressed inspectional timeline.
Key Takeaways The FDA’s recent Warning Letter activity involving Novo Nordisk and semaglutide-related pharmacovigilance processes may represent another major signal that FDA inspections are evolving beyond traditional manufacturing floor oversight and into enterprise-wide quality systems evaluation. As demand for GLP-1 therapies such as Ozempic and Wegovy continues to surge globally, FDA investigators appear to be…